!– Request: pharmaceutical-development/cohort-stratification-and-cdx-design –> <!– Matched Rewrite Rule: (.?.+?)(?:/([0-9]+))?/?$ –> <!– Matched Rewrite Query: pagename=pharmaceutical-development%2Fcohort-stratification-and-cdx-design&page= –> <!– Loaded Template: header-footer.php –>
Identify appropriate patient cohorts and enhance your companion diagnostic (CDx) design to improve stratification and success with QIAGEN Real-World Insights (RWI)
Creating an effective targeted drug involves defining the clinical trial patient cohorts and designing the biomarker profile for the companion diagnostic (CDx)—a lengthy and iterative process that requires extensive research, testing, and refinement.
QIAGEN Real-World Insights (RWI) provides the ability to rapidly mine real-world data and link genomic information to specific phenotypes to design a trial tailored to the desired patient cohort and optimized for the highest likelihood of success.
Capturing insights on a patient population within an indication of interest early and accurately empowers smarter trial design, faster implementation, precise stratification, resulting in an accelerated drug submission process.
QIAGEN RWI helps you:
The QIAGEN Real-World Insights (RWI) portfolio combines robust real-world genomic data from over 200,000 cancer cases and advanced analytics to identify appropriate patient cohorts and enhance companion diagnostic (CDx) designs.
To access RWI, you can:
Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, customize, and deliver within your timeline.
Choose the best biomarkers and cancer indications for your molecularly targeted therapies
Easily find the right patients and quickly move to recruitment and regulatory acceptance
Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses